The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) is an ongoing trial of 4–7 years aimed at comparing SU, insulin, DPP-4 inhibitor, and GLP-1 agonist for glycemic control and durability, which should help shed further light into the algorithm stratification [85]. The gene discussed is GLP1R; the disease is diabetes mellitus.